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When to initiate antiretroviral therapy (ART) in child-
ren and adults has been determined by disease stage 
and CD4 count or percentage. The starting criteria were 
based on cohort data and clinical experience. The main 
groups determining paediatric guidelines are from the 
USA, Europe (PENTA - Paediatric European Network for 
Treatment of AIDS) and the World Health Organization 
(WHO).1-3 With the advent of effective triple therapy 
from 1995, guidelines have adapted to new data. Ini-
tial staging clinical and immunological criteria were 
those of the Centers for Diseases Control and Preven-
tion (CDC).4 The staging criteria were based on North 
American experience and were not always appropriate 
for Africa. For example, failure to thrive, bronchiecta-
sis and pulmonary tuberculosis were not adequately 
addressed.
Although the CDC classification included CD4 deple-
tion, it was only with the HIV Prognostic Markers Col-
laborative Study (HPMCS), representing the combined 
data of 3 941 HIV-infected infants and children from 
the USA and Europe in the pre-highly active antiret-
roviral therapy (HAART) era, that the relationship be-
tween age and CD4 percentage became clearer.5 The 
study showed that the younger the infant, the higher 
the CD4 percentage or absolute count at which there 
was a high risk of disease progression or death within 
the next 12 months. As the CD4 count normally de-
clines with age until 5 years of age and the CD4 per-
centage remains stable, the CD4 percentage is used as 
a guideline until then (in the absence of lymphopenia). 
However, the CD4 count is an extremely accurate pre- 
dictor of outcome.6 These findings were subsequently 
incorporated into all paediatric guidelines.
The establishment of a WHO classification system in 
2006 helped to focus on conditions more frequently 
encountered in Africa.7 The system has 4 stages, with 
ART recommended for stages 3 and 4. The special vul-
nerability of young infants to rapid disease progres-
sion and death was not fully appreciated at this time, 
although allowance was made for initiating ART in HIV 
antibody-positive infants with severe disease before 
confirmation by HIV DNA polymerase chain reaction 
(PCR).
The decision on when to initiate ART in infants and child- 
ren has always been influenced by fears of long-term 
toxicity or antiretroviral (ARV) resistance if therapy is 
started too soon. Also, ARV choices for children are far 
more limited than for adults. Second-line therapy is es-
pecially unsatisfactory.
However, there is increasing realisation, especially from 
adult data, that delaying ART until the CD4 cell count 
falls below 350 cells/µl is associated with increased 
morbidity and mortality.8,9 ART is therefore recom-
mended at higher CD4 thresholds than previously.  
Mortality in HIV-infected infants is exceedingly high. 
The first data came from a study of combined outcome 
in nine vertical transmission prevention (VTP) studies 
conducted in sub-Saharan Africa.10 Thirty-five per cent 
of HIV-infected infants had died by 1 year of age and 
52.5% by 2 years of age. The ZVITAMBO study in Zim-
babwe showed a similar but slightly higher mortality 
in the first 2 years of life.11 For both studies, co-tri-
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moxazole prophylaxis for prevention of Pneumocystis 
pneumonia (PCP) was not given.
The Children with HIV Early Antiretroviral (CHER) trial is 
the first ARV trial to prospectively evaluate ART strat-
egies to inform ARV guidelines.12 Before this, limited 
cohort studies favoured early ART. For example, Faye et 
al. reported an improved outcome in 40 infants com-
mencing ART before 6 months of age compared with 
43 starting later. In the early group there was no dis-
ease progression versus 7 events, including 3 cases of 
encephalopathy, in those treated later.13 
CHER commenced in July 2005 in two South Afri-
can sites, the Perinatal HIV Research Unit (PHRU) in 
Soweto and the Children’s Infectious Diseases Clinical 
Research Unit (KID-CRU) at Tygerberg in the Western 
Cape. The hypothesis of the study is that early ART will 
have long-term benefit by delaying the need for con-
tinuous therapy. At the time of planning and initiation, 
the standard practice in infants was to initiate ART for 
a low CD4 percentage (<20% until August 2006 and 
25% thereafter, in the first year of life) or evidence of 
severe clinical disease.3,14 In the first part of the study, 
infants with baseline CD4 >25% were randomised to 
deferred ART (arm 1), where ART was initiated once 
treatment criteria were reached (CD4 <20% until Au-
gust 2006 and <25% thereafter or severe HIV disease), 
or early ART commencing before 12 weeks of age until 
either the first (arm 2) or second (arm 3) birthdays, with 
interruption of ART until indicated through CD4 deple-
tion (<20% after the first birthday) or clinical disease 
progression. For the first year of the study, deferred ART 
(arm 1) was compared with early ART (arms 2 and 3). 
On 20 June  2007, after the study had been open for 
2 years, the Data Safety Monitoring Board for CHER, 
noting significantly improved survival in subjects in the 
early ART arms, recommended that no infants be ran-
domised to deferred ART and that data until this time 
point be released.12 The difference in mortality and dis-
ease progression is shown in Fig. 1.
A key finding in CHER was high early mortality, mainly 
in the deferred arm, which diminished as the infants be-
came older (Table I). Also of note, however, is that mor-
tality was also higher early on in the early ART group, 
diminishing over time in the first year of the study. 
Subsequently, ARV guidelines for children through-
out the world incorporated the findings of CHER and 
recommended that all HIV-infected children below 12 
months of age start ART irrespective of CD4 status or 
disease progression.1, 2,15
More recently, a study by Bourne and colleagues, using 
birth and death data from Statistics South Africa be-
tween 1997 and 2002, showed a peak in post-neonatal 
mortality, rising each year directly proportional to the 
rising HIV antenatal seroprevalence.16 These data are 
shown in Fig. 2. Also of note is that neonatal deaths are 
not addressed. It is possible that HIV may contribute 
significantly to neonatal deaths as well.
These data, together with CHER, illustrate the enor-
mous dilemma and problems for child health pro-
grammes. In CHER the diagnostic HIV DNA PCR was 
done from 4 weeks of age with a 7-day turnaround 
time. In the public sector, the PCR is done at 6 weeks 
of age, to coincide with the 6-week immunisation visit. 
Turnaround time for the test results and then commu-
nication to the caregiver all take time during a period 
of great vulnerability.
One of the main problems is identifying HIV-infected 
children early and getting them into care. Because of 
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Fig. 1. Deferred ART is associated with a) a higher probability 
of death or b) first HIV event in the CHER trial. 
	 																	Death	rate		
	 														per	100	person-	
	 															years	(95%	CI)
Weeks	on	study*	 Early	ART	 Deferred	ART
0 - 13  9.8 (3.6 - 21.4) 40.6 (21 - 71)
>13 - 26 3.7 (0.4 - 13.2) 19.7 (6.4 - 45.9) 
>26 - 52 3.1 (0.4 - 11.2) 6.8 (0.8 - 24.7)
*Infants were <12 weeks of age at study entry.12
TABLE I. HIGH EARLY MORTALITY RATE IN THE  
CHER STUDY
Fig. 2. Early peak in infant mortality proportional to rising 
antenatal HIV seroprevalence, 1997 - 2002 (reproduced with 
permission from AIDS16).
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the importance of the caregiver in giving ARVs, previ-
ous guidelines emphasised adequate preparation and 
training over a number of weeks. Because of the new 
recognition of early infancy as a period of high mortal-
ity, there is a need to ‘fast-track’ preparation and also 
to continue training and support after having initiated 
ARVs.
Practical difficulties are illustrated by experience in 
the Tshwane district. In 2009, 82% of children newly 
referred to the Kalafong ART site had stage 3 or 4 dis-
ease, the majority being referred from the in- and out-
patient service. Of the 14 000 - 22 000 HIV-infected 
children thought to be in Tshwane, only between 3 000 
and 4 000 are receiving ART or are in care.
In this group there is less certainty on when to initiate 
ART. Ideally, decisions must be based on randomised 
studies. The PREDICT is underway in Thailand and Cam-
bodia and will assess the CD4 thresholds for therapy in 
children between 1 and 12 years of age. 
All guidelines recommend using absolute CD4 counts 
from 5 years of age. For simplicity, the WHO regards 
1 - 5 years of age as a single group, while the PENTA 
guidelines have 1 - 3 and 3 - 5 years of age. This group 
of children also represents a wide age spectrum. Clini-
cal disease stage is extremely important and the ma-
jority of children are symptomatic. The dissociation of 
CD4 from disease severity has been well documented 
in South African children.17 The HPMCS data, although 
showing a low risk of disease progression for higher 
CD4 percentages, still showed notable death and dis-
ease progression with CD4 >30% up to 6 years of 
age.5,6 
Initial data suggested that young children show excel-
lent immune restoration once ART is initiated, but more 
recent studies suggest a poorer response if therapy is 
delayed to CD4 <15%. Initial reports also suggested 
that viral suppression was difficult to achieve, espe-
cially in younger infants with extremely high viral loads. 
However, potent regimens and a better understanding 
of pharmacokinetics have improved outcomes. 
Importantly, health care providers caring for children 
often do not fully appreciate the extent of end-or-
gan damage. Mild cognitive and behavioural changes, 
milder forms of chronic lung disease, renal and hepatic 
disease and poor growth may easily be overlooked, 
leading to irreversible organ damage, growth failure 
and delayed puberty. 
In the 3C4KIDS, 2 510 children over a year of age from 
Africa and Brazil contributed 357 deaths and 3 769 
child-years at risk.18 None had access to ART, with 81% 
follow-up occurring on co-trimoxazole. The 12-month 
risk of death was higher than in the HPMCS for CD4 
count and percentage. Most importantly, when anae-
mia and failure to thrive were included, the CD4 thresh-
olds for predicting death or severe disease were much 
higher (Fig. 3). Both of these conditions are markers for 
advanced HIV disease. Most importantly, there was a 
real risk of death at high CD4 counts and percentages. 
For these reasons, our guidelines favour earlier ART be-
tween 1 and 5 years of age, in keeping with current US 
recommendations.2
There has been much progress in refining and improving 
ARV guidelines for children. More changes can be ex-
pected as knowledge advances. Most important, how-
ever, is the realisation that each child is unique and his 
or her individual and family circumstances need to be 
considered for maximum benefit.
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